Skip to main content

ADVERTISEMENT

ischemia

Case Q&A
03/07/2024

Stephen M. Milner, MBBS, BDS, DSc (Hon) FRCSE, FACS1; Ryan Mathis, MD2

Stephen M. Milner, MBBS, BDS, DSc (Ho...
This Case Q&A discusses pressure injuries, with context for spinal cord injuries.
This Case Q&A discusses pressure injuries, with context for spinal cord injuries.
This Case Q&A discusses pressure...
03/07/2024
ePlasty
Original Contribution
11/01/2021
The PREVAIL study evaluated the safety and effectiveness of a paclitaxel DCB for the treatment of coronary de novo and ISR lesions in patients with symptomatic ischemic heart disease.
The PREVAIL study evaluated the safety and effectiveness of a paclitaxel DCB for the treatment of coronary de novo and ISR lesions in patients with symptomatic ischemic heart disease.
The PREVAIL study evaluated the...
11/01/2021
Journal of Invasive Cardiology
Case Series
07/08/2020
CLI is the end stage of PAD and occurs in 1% to 3% of PAD patients. Patients commonly present with life-changing symptoms such as severe rest pain, ulcers, or gangrenous changes and reduced quality of life.
CLI is the end stage of PAD and occurs in 1% to 3% of PAD patients. Patients commonly present with life-changing symptoms such as severe rest pain, ulcers, or gangrenous changes and reduced quality of life.
CLI is the end stage of PAD and...
07/08/2020
Vascular Disease Management
Commentary
11/06/2008

Nicholas J. Morrissey, MD

Nicholas J. Morrissey, MD
The report by de Donato and colleagues on the impact of iloprost on outcomes after the treatment of acute ischemia provides insight into the mechanism and prevention of adverse effects related to ischemia and its treatment. The authors based...
The report by de Donato and colleagues on the impact of iloprost on outcomes after the treatment of acute ischemia provides insight into the mechanism and prevention of adverse effects related to ischemia and its treatment. The authors based...
The report by de Donato and...
11/06/2008
Vascular Disease Management